Will the Supreme Court Grant Cert in Myriad Patent Case?

Having trouble viewing images? View in web browser BIOTECH'S MOST RESPECTED NEWS SOURCE FOR MORE THAN 20 YEARS

Will the Supreme Court Grant Cert in Myriad Patent Case? By Mari Serebrov Washington Editor WASHINGTON – The Supreme Court is set to consider Friday whether it wants the last word on the patentability of Myriad Genetics Inc.’s claims on the BRCA1 and BRCA2 genes, used in diagnostics for breast and ovarian cancer. If the high court grants cert in The Association for Molecular Pathology v. Myriad Genetics Inc., it doesn’t necessarily mean the justices question the patentability of isolated DNA. Rather, they may want to add clarity to the split decision handed down by the U.S. Court of Appeals for the Federal Circuit last year, Jennifer Camacho, a partner with Greenberg Traurig, told BioWorld Today. Click here to read the issue featuring this article »	Solutions, in Right Order, Are Solutions to Repairing Nerves By Annette Breindl Science Editor Researchers have been able to rapidly repair peripheral nerves after injury in rats, in part through treatments that prevent the body’s own repair mechanisms from taking hold. They reported their fi ndings in two separate papers, both of which appeared in the Feb. 3, 2012, issue of the Journal of Neuroscience Research. One paper described details of the procedure, which combines a series of solutions with old-fashioned suturing of nerves. The other showed that when they used the procedure to repair cut or crushed sciatic nerves, “morphological continuity, action potential conduction, and behavioral functions [could] be consistently ( > 98 percent of trials), rapidly (minutes to days), dramatically (70-85 percent Click here to read the issue featuring this article »
Start-up Mnemosyne's Series A Raises $5.4M for CNS Platform By Marie Powers Staff Writer Mnemosyne Pharmaceuticals Inc., an emerging biotech targeting central nervous system (CNS) disorders, raised $5.4 million in a Series A fi nancing to advance its work on a class of molecules known as subunit selective NMDA receptor modulators (SNRMs). The round, led by Access BridgeGap Ventures and including existing investor Slater Technology Fund, will give the company a two-year runway in its preclinical drug discovery programs and support the identification of lead candidates in schizophrenia and other neuropsychiatric disorders, according to Kollol Pal, Mnemosyne’s president and CEO. Click here to read the issue featuring this article »	Alynlam Flexes Fundraising Muscles, Adds $80M Publicly By Catherine Shaffer Staff Writer Alnylam Pharmaceuticals Inc.’s underwritten public offering of 7.5 million shares at $10.75 apiece sent shares of the Cambridge, Mass.-based biotech surging more than 14 percent Wednesday as investors showed their approval of its pipeline and partnering power. Net proceeds of about $75.8 million will boost the company’s cash to about $336.5 million, providing plenty of funding for clinical development of ALN-TTR02 in transthyretin amyloidosis and ALN-APC in hemophilia, with enough left over to help land some attractivepartnerships for ALN-PCS (hypercholesterolemia), ALNHPN (refractory anemia) and ALN-VSP (liver cancer). Analyst Edward A. Tenthoff, of Piper Jaffray and Co., noted that the cash should last through 2014 Click here to read the issue featuring this article »

Thompson Publishing Group | 805 15th Street, NW, 3rd Floor | Washington, DC 20005 | service@thompson.com | © 2011 Thompson Publishing Group. All rights reserved.

You have received this email because you registered at BioSpace. BioSpace regularly sends emails to active subscribers on behalf of our advertising partners or to promote our own products and services. If you would like to stop receiving all email communications from BioSpace, you can unsubscribe at any time by clicking here. BioSpace 6465 South Greenwood Plaza, Suite 400, Centennial, CO 80111, U.S. (888) BIOSPACE